MX369801B - Compuesto heterociclico sustituido con halogeno. - Google Patents
Compuesto heterociclico sustituido con halogeno.Info
- Publication number
- MX369801B MX369801B MX2015008479A MX2015008479A MX369801B MX 369801 B MX369801 B MX 369801B MX 2015008479 A MX2015008479 A MX 2015008479A MX 2015008479 A MX2015008479 A MX 2015008479A MX 369801 B MX369801 B MX 369801B
- Authority
- MX
- Mexico
- Prior art keywords
- group
- halogen
- atom
- heterocyclic compound
- ring
- Prior art date
Links
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 abstract 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 229930192474 thiophene Natural products 0.000 abstract 1
- -1 thiophene compound Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012286425 | 2012-12-28 | ||
| JP2013097171 | 2013-05-02 | ||
| PCT/JP2013/085277 WO2014104372A1 (ja) | 2012-12-28 | 2013-12-27 | ハロゲン置換へテロ環化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015008479A MX2015008479A (es) | 2015-09-23 |
| MX369801B true MX369801B (es) | 2019-11-21 |
Family
ID=51021433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008479A MX369801B (es) | 2012-12-28 | 2013-12-27 | Compuesto heterociclico sustituido con halogeno. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10000463B2 (enExample) |
| EP (2) | EP2940013B1 (enExample) |
| JP (3) | JP6176258B2 (enExample) |
| KR (1) | KR102189166B1 (enExample) |
| CN (2) | CN104884447B (enExample) |
| AU (1) | AU2013366898B2 (enExample) |
| BR (1) | BR112015015275B1 (enExample) |
| CA (1) | CA2896701C (enExample) |
| DK (2) | DK3360869T3 (enExample) |
| ES (2) | ES2667798T3 (enExample) |
| MX (1) | MX369801B (enExample) |
| RU (2) | RU2756506C2 (enExample) |
| WO (1) | WO2014104372A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2940013B1 (en) * | 2012-12-28 | 2018-02-21 | Ube Industries, Ltd. | Halogen-substituted heterocyclic compound |
| SG11201507459YA (en) | 2013-03-15 | 2015-10-29 | Epigen Biosciences Inc | Heterocyclic compounds useful in the treatment of disease |
| JP2014231508A (ja) * | 2013-05-02 | 2014-12-11 | 宇部興産株式会社 | ハロゲン置換へテロ環化合物 |
| WO2015199234A1 (ja) * | 2014-06-27 | 2015-12-30 | 宇部興産株式会社 | ハロゲン置換へテロ環化合物の塩 |
| JPWO2017086430A1 (ja) * | 2015-11-20 | 2018-09-06 | 宇部興産株式会社 | Ｎａｓｈの治療又は予防のための医薬組成物 |
| IL289951B2 (en) * | 2019-07-30 | 2025-10-01 | Taisho Pharmaceutical Co Ltd | Urea compound as an LPA1 receptor antagonist |
| CN114728168B (zh) | 2019-11-15 | 2024-04-09 | 吉利德科学公司 | 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途 |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| US11702407B2 (en) | 2020-06-03 | 2023-07-18 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| CN111909170B (zh) * | 2020-09-11 | 2022-08-12 | 吉林奥来德光电材料股份有限公司 | 一种有机电致发光化合物、其制备方法以及包含该有机电致发光化合物的有机电致发光器件 |
| JP7859068B2 (ja) * | 2021-01-28 | 2026-05-15 | 大正製薬株式会社 | Ｌｐａ１受容体を拮抗するウレア化合物を有効成分として含有する医薬 |
| AU2022273631B2 (en) | 2021-05-11 | 2025-04-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| CA3222642A1 (en) | 2022-12-12 | 2024-06-12 | Bmic Llc | Downstream uses for briquettes and other forms of powder from asphalt shingle waste |
| WO2026094986A1 (en) * | 2024-11-01 | 2026-05-07 | Hilung Inc. | Dry powder pharmaceutical composition for inhalation comprising small molecule lpa1 antagonist and process for preparation thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE420878T1 (de) * | 2000-02-18 | 2009-01-15 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| EP1364659B1 (en) | 2001-02-08 | 2009-11-11 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| JP4692281B2 (ja) * | 2003-08-05 | 2011-06-01 | 味の素株式会社 | 新規アゾール化合物 |
| MX2011003383A (es) | 2008-09-29 | 2011-04-21 | Lilly Co Eli | Modulador selectivo del receptor de estrogeno para el tratamiento de osteoartritis. |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| JP2013501064A (ja) | 2009-08-04 | 2013-01-10 | アミラ ファーマシューティカルス，インコーポレーテッド | リゾホスファチジン酸受容体アンタゴニストとしての化合物 |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| WO2011091167A2 (en) | 2010-01-22 | 2011-07-28 | The General Hospital Corporation | Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases |
| WO2011159635A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions |
| WO2011159633A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| WO2011159632A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye |
| CN107721940A (zh) | 2010-12-07 | 2018-02-23 | 阿米拉制药公司 | 多环lpa1拮抗剂及其使用 |
| WO2012078593A2 (en) | 2010-12-07 | 2012-06-14 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists and uses thereof |
| CN103596947A (zh) | 2011-04-05 | 2014-02-19 | 艾米拉医药股份有限公司 | 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物 |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| EP2744807A4 (en) | 2011-08-15 | 2015-03-04 | Intermune Inc | COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS |
| EP2940013B1 (en) * | 2012-12-28 | 2018-02-21 | Ube Industries, Ltd. | Halogen-substituted heterocyclic compound |
-
2013
- 2013-12-27 EP EP13868493.1A patent/EP2940013B1/en active Active
- 2013-12-27 EP EP18157384.1A patent/EP3360869B1/en active Active
- 2013-12-27 WO PCT/JP2013/085277 patent/WO2014104372A1/ja not_active Ceased
- 2013-12-27 KR KR1020157019230A patent/KR102189166B1/ko active Active
- 2013-12-27 JP JP2014554626A patent/JP6176258B2/ja active Active
- 2013-12-27 ES ES13868493.1T patent/ES2667798T3/es active Active
- 2013-12-27 ES ES18157384T patent/ES2825031T3/es active Active
- 2013-12-27 RU RU2018109925A patent/RU2756506C2/ru active
- 2013-12-27 RU RU2015131139A patent/RU2649398C2/ru active
- 2013-12-27 DK DK18157384.1T patent/DK3360869T3/da active
- 2013-12-27 CN CN201380068911.1A patent/CN104884447B/zh active Active
- 2013-12-27 DK DK13868493.1T patent/DK2940013T3/en active
- 2013-12-27 MX MX2015008479A patent/MX369801B/es active IP Right Grant
- 2013-12-27 BR BR112015015275-9A patent/BR112015015275B1/pt active IP Right Grant
- 2013-12-27 AU AU2013366898A patent/AU2013366898B2/en active Active
- 2013-12-27 CN CN201710949188.8A patent/CN107698555B/zh active Active
- 2013-12-27 CA CA2896701A patent/CA2896701C/en active Active
-
2015
- 2015-06-26 US US14/752,623 patent/US10000463B2/en active Active
-
2017
- 2017-07-11 JP JP2017135811A patent/JP6414286B2/ja active Active
-
2018
- 2018-05-08 US US15/974,494 patent/US10597375B2/en active Active
- 2018-10-03 JP JP2018188246A patent/JP6569792B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015008479A (es) | Compuesto heterociclico sustituido con halogeno. | |
| MX2012015023A (es) | Derivado novedoso de nicotinamida o sal del mismo. | |
| MX2009004920A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1. | |
| PH12015502232A1 (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| PH12017501192A1 (en) | Certain amino-pyridazines, compositions thereof, and methods of their use | |
| MY152972A (en) | Azabicyclo compound and salt thereof | |
| PH12016502037A1 (en) | Certain amino-pyrimidines, compositions thereof, and methods for their use | |
| ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
| ES2570756T3 (es) | Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa | |
| TW201129556A (en) | Novel antiplatelet agent | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| PE20160523A1 (es) | Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis | |
| IN2014DN07509A (enExample) | ||
| MY169179A (en) | Novel piperidine compound or salt thereof | |
| PH12014501540A1 (en) | 4-(benzoimidazol-2-yl) - thiazole compounds and related aza derivatives | |
| PH12018502012B1 (en) | Griseofulvin compound | |
| IN2012DN00770A (enExample) | ||
| PH12014502663B1 (en) | Aromatic heterocyclic derivative and pharmaceutical | |
| MX2013005753A (es) | Nuevos derivados de biaril amida. | |
| MX344474B (es) | Nuevos derivados de furanona. | |
| PH12013501856A1 (en) | Novel octahydrothienoquinoline derivative, pharmaceutical composition comprising derivative, and use of these | |
| MX359399B (es) | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. | |
| MY164789A (en) | Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | |
| MX2015004325A (es) | Procesos para la sintesis de 2-amino-4, 6-dimetoxibenzamida y otros compuestos de benzamida. | |
| IN2012DN01251A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |